02954nam 2200649Ia 450 991045568280332120200520144314.01-283-90371-71-4175-0513-31-84642-315-5(CKB)111087028275302(EBL)290738(OCoLC)567905696(SSID)ssj0000397650(PQKBManifestationID)11250628(PQKBTitleCode)TC0000397650(PQKBWorkID)10358230(PQKB)10234393(MiAaPQ)EBC290738(Au-PeEL)EBL290738(CaPaEBR)ebr10064495(CaONFJC)MIL421621(EXLCZ)9911108702827530220020211d2002 uy 0engur|n|---|||||txtccrLearning, practice and assessment[electronic resource] signposting the portfolio /Mark Doel, Catherine Sawdon and Diane MorrisonLondon Jessica Kingsley20021 online resource (178 p.)Description based upon print version of record.1-84985-130-1 1-85302-976-9 Includes bibliographical references and index.Learning, Practice and Assessment: Signposting the Portfolio; Contents; Acknowledgements; Introduction; Part 1: Integrating learning, practice and assessment; 1. Introduction to Part 1; 2. Professional practice; 3. Learning professional practice; 4. Assessing professional practice; 5. Learning and assessing; Part 2: A Signposted Portfolio; Section 1. Introduction to the portfolio; Section 2. Planning the group; Section 3. The early stage; Section 4. The work phase; Section 5. Group processes; Section 6. Endings; Section 7. Evaluating the group; Section 8. Power and oppressionSection 9. Other perspectivesPart 3: Postscript; 6. Conclusion; References; Subject Index; Author IndexThis is a comprehensive guide to integrating assessment, learning and practice, reflecting current concerns in health and social care. The authors - an academic, a training officer and a practitioner - present complementary perspectives to bring theory and practice closer together.Community health aidesTraining ofGreat BritainEmployment portfoliosGreat BritainSocial workersTraining ofGreat BritainElectronic books.Community health aidesTraining ofEmployment portfoliosSocial workersTraining of361.30941Doel Mark451303Morrison Diane1054315Sawdon Catherine736970MiAaPQMiAaPQMiAaPQBOOK9910455682803321Learning, practice and assessment2486806UNINA04288nam 22004695 450 991035023940332120200706142901.0981-13-1489-610.1007/978-981-13-1489-6(CKB)4100000007104049(DE-He213)978-981-13-1489-6(MiAaPQ)EBC5560083(PPN)231458924(EXLCZ)99410000000710404920181019d2019 u| 0engurnn|008mamaatxtrdacontentcrdamediacrrdacarrierAdvances in Diagnosis and Management of Cutaneous Adverse Drug Reactions Current and Future Trends /edited by Neil H. Shear, Roni P. Dodiuk-Gad1st ed. 2019.Singapore :Springer Singapore :Imprint: Adis,2019.1 online resource (XII, 314 p. 95 illus., 91 illus. in color.) 981-13-1488-8 Section I. Introduction -- 1. Introduction: Classification, Terminology, Epidemiology and Etiology of Cutaneous Adverse Drug Reactions -- Section II. Pathomechanisms of Cutaneous Adverse Drug Reactions -- 2. Immunology of Cutaneous Adverse Drug Reactions -- 3. Pharmacogenomics and Cutaneous Adverse Drug Reactions -- 4 Viral Reactivation in Cutaneous Adverse Drug Reactions -- 5. Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions -- Section III. Clinical Perspectives of Cutaneous Adverse Drug Reactions -- 6. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis) -- 7. Drug Reaction with Eosinophilia and Systemic Symptoms -- 8. Acute Generalized Exanthematous Pustulosis -- 9. Urticarial Reactions to Drugs -- 10. Dermatological Adverse Events from Cancer Treatments -- 11. Cutaneous Adverse Drug Reactions in Pediatric Population -- 12. Cutaneous Drug Reactions in the Elderly -- 13. Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Patients -- 14. Cutaneous Adverse Drug Reactions from Anti-Tuberculosis Treatment -- Section IV. Approach to the Patient with a Cutaneous Adverse Drug Reaction -- 15. Practical Approach to Diagnosis and Management of Cutaneous Adverse Drug Reactions -- 16. Histopathology of Severe Drug Eruptions -- 17. Evaluation of Drug Safety Literature: A Guide for the Practicing Dermatologist -- 18. In vitro and in vivo tests in Cutaneous Adverse Drug Reactions -- 19. Pharmacovigilance of Cutaneous Adverse Drug Reactions -- Section V. Epilogue -- 20. Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions -- 21. Atlas of Cutaneous Adverse Drug Reactions.This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context.PharmacyPharmacologyDrug Safety and Pharmacovigilancehttps://scigraph.springernature.com/ontologies/product-market-codes/H69010Pharmacology/Toxicologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B21007Pharmacy.Pharmacology.Drug Safety and Pharmacovigilance.Pharmacology/Toxicology.353.998Shear Neil Hedthttp://id.loc.gov/vocabulary/relators/edtDodiuk-Gad Roni Pedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910350239403321Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions1734890UNINA